News
-
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Bausch Health's UCERIS listed on public drug plans in 5 Canadian provinces. The rectal foam treats mild to moderate ulcerative colitis. Patients gaining insured access to effective treatment -
COMMUNIQUÉ DE PRESSE
Bausch Health, Canada Inc. annonce les premières inscriptions de la mousse en aérosol (Pr)UCERIS(MC) (budésonide) aux listes des médicaments remboursés par les régimes d’assurance publics pour les adultes atteints de colite ulcéreuse distale lég
Bausch Health annonce l'inscription d'UCERIS, mousse en aérosol pour traiter la colite ulcéreuse, aux listes de médicaments remboursés par les régimes d'assurance publics de 5 provinces canadiennes -
-
-
COMMUNIQUÉ DE PRESSE
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Salix Pharmaceuticals releases fourth annual Patient Perspectives IBS Impact Report, revealing insights on the experiences of IBS/CIC patients and the need for more authentic conversations. Survey conducted in partnership with FDU Poll -
-
-
COMMUNIQUÉ DE PRESSE
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Bausch Health Companies Inc. and Salix Pharmaceuticals are supporting a Phase 2 study of RELISTOR in head and neck cancer patients. The study aims to evaluate the potential of methylnaltrexone bromide as a treatment option